Teva scrubs 200-plus Orange Book patents after FTC turns the screw

Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ orders Teva to delist five patents from Orange Book

24 December 2024 Dispute stems from Amneal’s efforts to market generic version of Teva’s inhaler for treating asthma | Precedential decision could restrict how brand-name pharmaceutical companies use the Orange Book to extend market exclusivity.

Americas

Teva fights for re-listing of inhaler patents at US appeals court

12 November 2024 Oral arguments heard in case between Teva and generics maker Amneal over inhaler patents | Teva says district court and Amneal asked court to ‘slice apart new drug application’.

More features

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Novo Nordisk ramps up semaglutide defence as generics lurk

Cooley drafts in 30-strong life sciences team from rival

US govt backs Hikma over ‘skinny label’ rules

Marks & Clerk adds multi-jurisdictional disputes expert

USPTO issues guidance to support patent eligibility declarations

Chest-worn heart monitor tech flatlines in US patent appeal

Novo Nordisk India strategy suffers semaglutide patent setback

Teva scrubs 200-plus Orange Book patents after FTC turns the screw

More on this story

Editor's picks

Editor's picks

More features